The decline in oestrogen levels starting in women’s 40s, leads to a chronic hormonal imbalance affecting women from this stage onwards. This change dramatically impacts women’s quality of life, from the onset of ‘menopausal’ signs to the progression of post-menopausal signs.
The in-house-developed DT56a is at the core of each product in the line, targeting the oestrogen receptors while each product contains different vitamins and minerals, boosting the beneficial impact on the target tissue.
DT56a, is a non-hormonal proprietary API, originating from the soybean plant, processing the 20 amino acids within the soybean, creating, a unique compound that has been modulated to form the desired effect within the woman’s body, by bonding to the oestrogen receptors without being recognised by the body as oestrogen, thus developing a non-hormonal botanical therapy that was declared in 2017 as the 1st line treatment for the management of menopause at the European Society of Gynaecology.
DT56a, a standardised compound with a clear fingerprint, mimics the structures that are recognised by oestrogen receptors in the woman’s body as oestrogen, bound together with either a co-activator or co-repressor, depending on the tissue forming a Selective oestrogen Receptor Modulator, having either an agonistic (activation) or antagonistic (blocking) effect on the oestrogen receptors.